Want to see NBP full AI Analyst Report?
NovaBridge Biosciences (NBP) Stock Statistics & Valuation Metrics
Total Valuation
NovaBridge Biosciences has a market cap or net worth of $138.62M. The enterprise value is $39.26M.
- Market Cap
- $138.62M
- Enterprise Value
- $39.26M
Share Statistics
NovaBridge Biosciences has 115,381,690 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 115,381,690
- Owned by Insiders
- 0.87%
- Owned by Institutions
- 1.29%
Financial Efficiency
NovaBridge Biosciences’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -40.20%.
- Return on Equity (ROE)
- -0.20
- Return on Assets (ROA)
- -0.18
- Return on Invested Capital (ROIC)
- -40.20%
- Return on Capital Employed (ROCE)
- -0.40
- Revenue Per Employee
- 0
- Profits Per Employee
- -220.49K
- Employee Count
- 30
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of NovaBridge Biosciences is -2.09. NovaBridge Biosciences’s PEG ratio is -0.16.
- PE Ratio
- -2.09
- PS Ratio
- 0.00
- PB Ratio
- 0.69
- Price to FCF
- -3.90
- Price to Operating Cash Flow
- -4.03
- PEG Ratio
- -0.16
Income Statement
In the last 12 months, NovaBridge Biosciences had revenue of 0 and earned -6.61M in profits. Earnings per share was -0.16.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -13.48M
- Pretax Income
- -12.63M
- Net Income
- -6.61M
- EBITDA
- -12.62M
- Earnings Per Share (EPS)
- -0.16
Cash Flow
In the last 12 months, operating cash flow was -34.30M and capital expenditures -987,825, giving a free cash flow of -35.29M billion.
- Operating Cash Flow
- -34.30M
- Free Cash Flow
- -35.29M
- Free Cash Flow per Share
- -0.30
Dividends & Yields
NovaBridge Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -28.88%
- Earnings Yield
- -39.96%
Stock Price Statistics
- Beta
- 1.21
- 52-Week Price Change
- -73.74%
- 50-Day Moving Average
- 1.51
- 200-Day Moving Average
- 2.16
- Relative Strength Index (RSI)
- 28.43
- Average Volume (3m)
- 432.57K
Important Dates
NovaBridge Biosciences upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 20, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
NovaBridge Biosciences as a current ratio of 8.09, with Debt / Equity ratio of 1.33%
- Current Ratio
- 8.09
- Quick Ratio
- 8.09
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.35
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, NovaBridge Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
NovaBridge Biosciences EV to EBITDA ratio is 1.16, with an EV/FCF ratio of 1.81.
- EV to Sales
- 0.00
- EV to EBITDA
- 1.16
- EV to Free Cash Flow
- 1.81
- EV to Operating Cash Flow
- 1.87
Balance Sheet
NovaBridge Biosciences has $190.85M in cash and marketable securities with $4.46M in debt, giving a net cash position of $186.39M billion.
- Cash & Marketable Securities
- $190.85M
- Total Debt
- $4.46M
- Net Cash
- $186.39M
- Net Cash Per Share
- $1.62
- Tangible Book Value Per Share
- $1.74
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for NovaBridge Biosciences is $9.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $9.00
- Price Target Upside
- 653.14% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 6
- AI Score
- 49
